As Pfizer celebrates a decade of Viagra, many companies are racing to develop drugs for what they regard as the potentially lucrative “female s-xual dysfunction” market, writes Ray Moynihan.
As Pfizer celebrates a decade of Viagra, many companies are racing to develop drugs for what they regard as the potentially lucrative “female s-xual dysfunction” market, writes Ray Moynihan.